新型抗菌补片修复腹壁疝缺损的临床前生物检测
本研究在兔模型中开发并评估了负载利福平的羧甲基纤维素凝胶抗菌补片涂层。体外实验显示该凝胶对金黄色葡萄球菌和表皮葡萄球菌有良好抗菌活性且对成纤维细胞无害。体内实验表明,涂层补片能完全清除细菌并实现最佳组织整合,而未涂层或单纯凝胶涂层补片则出现感染迹象和组织整合受损。
要点
- 利福平-羧甲基纤维素凝胶涂层补片在兔腹壁疝模型中完全清除金黄色葡萄球菌和表皮葡萄球菌。
- 涂层补片实现最佳组织整合,而未涂层或单纯凝胶涂层补片出现感染和组织整合受损。
- 血液中未检测到利福平,提示局部应用安全性良好。
核心结论
- 将补片浸泡于利福平-羧甲基纤维素凝胶可有效抑制细菌黏附而不影响组织修复。
研究设计与样本
- 临床前动物实验:在新西兰白兔中创建部分腹壁缺损(5×2 cm),接种0.25 mL 10^6 CFU金黄色葡萄球菌或表皮葡萄球菌(各n=17),使用未涂层(n=3)、羧甲基纤维素凝胶涂层(n=7)或利福平-羧甲基纤维素凝胶涂层(n=7)的轻质单丝大孔聚丙烯补片修复。
主要发现
- 体外:利福平-羧甲基纤维素凝胶对金黄色葡萄球菌和表皮葡萄球菌有强活性,对成纤维细胞无害。
- 体内:利福平-羧甲基纤维素凝胶涂层植入物显示完全细菌清除和最佳组织整合,与葡萄球菌菌株无关。
- 未涂层和羧甲基纤维素凝胶涂层植入物显示宏观/微观感染迹象和组织整合受损。
- 巨噬细胞反应在利福平-羧甲基纤维素凝胶植入物中低于未涂层补片(金黄色葡萄球菌/表皮葡萄球菌;P < .01)和羧甲基纤维素凝胶植入物(表皮葡萄球菌;P < .05)。
- 血液中利福平水平未检测到。
临床怎么用
- 该抗菌凝胶涂层补片可能作为预防术后补片感染的简易有效策略,但需进一步临床研究验证。
局限性
- 本研究为临床前动物模型,样本量有限,结果需在人体试验中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In hernia surgery, soaking of meshes in antibiotics before implantation is a prophylactic strategy for minimizing the risk of infection while providing minimal, local, drug doses. This study describes the development and application of an antibacterial mesh coating comprising a carboxymethylcellulose gel loaded with rifampicin in a preclinical model of Staphylococcus aureus and S. epidermidis infection in rabbits. METHODS: Antibacterial activity and cytocompatibility (with fibroblasts) of unloaded carboxymethylcellulose gel and 0.13 mg/mL rifampicin-carboxymethylcellulose gel were assessed in vitro. Then, partial abdominal wall defects (5 × 2 cm) were created in New Zealand white rabbits (n = 34), the wound inoculated with 0.25 mL of 106 CFU Staphylococcus aureus/ S. epidermidis (n = 17 each), and the defect then repaired with a lightweight, monofilament, large pore polypropylene mesh either uncoated (n = 3) or coated with carboxymethylcellulose gel (n = 7) or rifampicin-carboxymethylcellulose gel (n = 7). By postoperative day 14, coating performance was evaluated by determining bacterial adhesion (via sonication), host tissue incorporation (via histology), macrophage response via immunostaining), and bloodstream drug diffusion (via high-performance liquid chromatography). RESULTS: In vitro, rifampicin-carboxymethylcellulose gel demonstrated great activity against Staphylococcus aureus/S. epidermidis, while being innocuous for fibroblasts. In vivo, rifampicin-carboxymethylcellulose gel-coated implants displayed full bacterial clearance and optimal tissue integration, irrespective of the strain of Staphylococcus. In contrast, uncoated and carboxymethylcellulose gel-coated implants exhibited macro/microscopic signs of infection and impaired tissue integration. Macrophage responses were less in rifampicin-carboxymethylcellulose gel implants than in uncoated mesh (Staphylococcus aureus/S. epidermidis; P < .01) and carboxymethylcellulose gel (S. epidermidis; P < .05) implants. Bloodstream levels of rifampicin were undetectable. CONCLUSION: Soaking meshes in rifampicin-carboxymethylcellulose gel inhibited effectively the bacterial adhesion to the mesh without compromising the tissue repair. This antibiotic gel constitutes an easy-to-use and effective prophylactic strategy that potentially reduce the prevalence of postoperative mesh infection.
引用
- Pérez-Köhler B, Benito-Martínez S, García-Moreno F, et al. Preclinical bioassay of a novel antibacterial mesh for the repair of abdominal hernia defects. Surgery. 2019. PMID: 31785825. doi:10.1016/j.surg.2019.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。